Stocks · News reference
Filed: 2026-10-06 AccNo: 0001641489-26-000032 Size: 6 MB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the Company has completed
vTv Therapeutics announced that management will participate in two investor conferences in September 2026: the H.C. Wainwright 28th Annual Global Investment Conference on September 16 and the 5th Annual ROTH Healthcare Opportunities Conference on September 29. The company continues advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes, with its Phase 3 CATT1 trial expected to complete enrollment in Q3 2026.
HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and lowers the price target from $45 to $42.